BMS opts-in on Evotec’s neurodegenerative medicine
Bristol Myers Squibb (BMS) has opted-in to an exclusive global license for Evotec’s neurodegenerative drug EVT8683.
We use necessary cookies to make our site work. We'd also like to set analytical cookies to help us improve our service, but we'd like your permission first. Please choose which cookies you're happy for us to set.